PhXA41 is not inferior to timolol in reducing intra-ocular pressure
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
267
Pfizer Investigational Site
Hellerup, Denmark
Pfizer Investigational Site
Vejle, Denmark
Pfizer Investigational Site
Oulu, Finland
to demonstrate the IOP-reducing effect of PhXA41 is comparable to that of timolol at the end of 6 months of treatment.
Time frame: 6 mos
to demonstrate the IOP-reducing effect of PhXA41 administered in the morning is equivalent the effect of PhXA41 administered in the evening
Time frame: 6 mos
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Pfizer Investigational Site
Bergen, Norway
Pfizer Investigational Site
Oslo, Norway
Pfizer Investigational Site
Trondheim, Norway
Pfizer Investigational Site
Gothenburg, Sweden
Pfizer Investigational Site
Huddinge, Sweden
Pfizer Investigational Site
Linköping, Sweden
Pfizer Investigational Site
Lund, Sweden
...and 3 more locations